insulin aspart

(redirected from Novomix 30)
Also found in: Medical.

insulin as·part

 (ăs′pärt′)
n.
A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by the substitution of aspartic acid for proline in the B chain, used in the treatment of type 1 and type 2 diabetes.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
5 December 2011 - Danish pharma major Novo Nordisk A/S (CPH:NOVO B) announced today positive results with its insulin analogues NovoMix 30, Levemir and NovoRapid, including better glucose control and improved rates of hypoglycaemia in patients with type 2 diabetes.
(11.) NovoMix 30 FlexPen prospektus bilgisi, Novo Nordisk Production SAS 45, Avenue d'Orleans, F-28002 Chartres, Fransa.
They were randomized to one of three regimens in the first year: prandial insulin aspart (NovoRapid) three times daily, biphasic insulin aspart (NovoMix 30) twice daily, or basal detemir (Levemir) once or twice daily.
They were randomized to one of three supplemental insulin regimens in the first year: prandial insulin aspart (NovoRapid) three times daily, biphasic insulin aspart (NovoMix 30) twice daily, or basal detemir (Levemir) once daily, or twice if needed.
Each patient took the biphasic insulin (marketed as NovoMix 30) as directed by their clinician for 26 weeks, and their data was recorded at baseline, three months and at the final visit.
In this study, 708 adults with type 2 diabetes-and an Hb [A.sub.1c] level between 7% and 10% despite maximal therapy with metformin and a sulfonylurea--were randomized to 1 of 3 groups: (1) twice-daily biphasic insulin aspart 30 (NovoMix 30); (2) 3-times-daily preprandial insulin aspart (NovoRapid); and (3) oncedaily basal insulin detemir at bedtime (Levemir).
Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.